Dana Farber Cancer Institute SC — Boston, Massachusetts

Dana Farber Cancer Institute SC is a clinical research site located in Boston, Massachusetts, United States 02215.

Crixeo Health Trust Score: 67/100 (FAIR). This profile has not yet been claimed by the site owner.

Dana Farber Cancer Institute SC has participated in 5 clinical trials.

Therapeutic areas: c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM, Advanced NET of GI Origin, Advanced NET of Lung Origin.

Sponsors: Novartis Pharmaceuticals.

Sponsor Feasibility Report

Trust Score: 67/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana Farber Cancer Institute SC?

Dana Farber Cancer Institute SC has a Crixeo Trust Score of 67/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana Farber Cancer Institute SC conducted?

Dana Farber Cancer Institute SC has 5 clinical trials on record. Their work covers c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM, Advanced NET of GI Origin, Advanced NET of Lung Origin.

Is Dana Farber Cancer Institute SC accredited by Crixeo Health?

Dana Farber Cancer Institute SC has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Dana Farber Cancer Institute SC?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.